UNSPSC 51284020: Chlortetracycline hydrochloride

This classification denotes a tetracycline antibiotic with the molecular formula C22H23ClN2O8.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O1GX33ON8R, chemically known as 2-(amino-hydroxy-methylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione but more generally known as chlortetracycline hydrochloride, which bears US NIH Compound Identifier 5280963.

UNSPSC 51284020 Chlortetracycline hydrochloride is a Commodity code that nominally describes a specific antibiotic active pharmaceutical ingredient, but recent state and local solicitations tagged with this code show minimal alignment with that scope. The recent opportunities block contains four records, three of which are plainly unrelated to chlortetracycline hydrochloride: the Seminole County procurement seeks naloxone and drug deactivation systems; the City of Tampa procurement solicits medical and first aid supplies for fire rescue operations; and the Texas HHS Commission RFI seeks information on direct-to-manufacturer prescription programs. Only the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products sits within pharmaceutical procurement, though it does not name chlortetracycline hydrochloride specifically. The code shows little relevant recent activity, suggesting either sparse demand for chlortetracycline hydrochloride specifically at the state and local level, or misclassification of opportunities in the underlying procurement records.

Given the mismatch between the code's nominal scope and the recent solicitations, state and local governments do not appear to be actively procuring chlortetracycline hydrochloride as a standalone input through formal RFP, RFQ, IFB, or ITB processes at present. The opportunities that are genuinely pharmaceutical-related — such as the MMCAP cooperative purchasing agreement posted January 20, 2026 with a response deadline of March 26, 2026 — target generic multi-source pharmaceuticals through established wholesaler networks (AmerisourceBergen, Cardinal Health, and Morris & Dickson) and do not isolate this particular active ingredient. State and local procurement activity under this code does not support a near-term business development strategy focused on chlortetracycline hydrochloride supply.